Literature DB >> 9768715

Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators.

S N Singh1, S G Fisher, P E Carson, R D Fletcher.   

Abstract

OBJECTIVES: This study sought to determine the prevalence and significance of nonsustained ventricular tachycardia (NSVT) in patients with premature ventricular contractions (PVCs) and heart failure treated with vasodilator therapy.
BACKGROUND: Heart failure patients with ventricular arrhythmia and NSVT have a significantly increased risk of premature cardiac death. Recently there has been the question of whether these arrhythmias are expressions of a severely compromised ventricle or are they independent risk factors. We, therefore, determined the prevalence and significance of NSVT in patients with PVCs and heart failure and on vasodilator therapy.
METHODS: Twenty-four hour ambulatory recordings were done at randomization, at 2 weeks, at months 1, 3, 6, 9 and 12 and then every 6 months in 674 patients with heart failure and on vasodilator therapy. The median period of follow-up was 45 months (range 0 to 54).
RESULTS: Nonsustained ventricular tachycardia was present in 80% of all patients. Patients without (group 1) and with (group 2) NSVT were balanced for variables: age, etiology of heart disease, New York Heart Association (NYHA) functional class, use of amiodarone and diuretics and left ventricular diameter by echocardiogram. However, group 1 patients had significantly less beta-adrenergic blocking agent use and higher ejection fraction (EF) (p < 0.002 and p < 0.001, respectively). Survival analysis for all deaths showed a greater risk of death among group 2 patients (p=0.01). Similarly, sudden death was increased in group 2 patients (p=0.02, risk ratio 1.8). After adjusting for the above variables, only EF (p=0.001) and NYHA class (p=0.01) were shown to be independent predictors of survival. Nonsustained ventricular tachycardia showed a trend (p=0.07) as an independent predictor for all-cause mortality but not for sudden death. Only EF was an independent predictor for sudden death.
CONCLUSIONS: Nonsustained ventricular tachycardia is frequently seen in patients with heart failure and may be associated with worsened survival by univariate analysis. However, after adjusting other variables, especially for EF, NSVT was not an independent predictor of all-cause mortality or sudden death. These results have serious implications in that suppression of these arrhythmias may not improve survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768715     DOI: 10.1016/s0735-1097(98)00338-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  23 in total

Review 1.  Electrocardiographic predictors of arrhythmic death.

Authors:  Michael G McLaughlin; Peter J Zimetbaum
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-10       Impact factor: 1.468

2.  Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls.

Authors:  Thomas Pezawas; André Diedrich; Robert Winker; David Robertson; Bernhard Richter; Li Wang; Daniel W Byrne; Herwig Schmidinger
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-09-27

3.  Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia.

Authors:  Dalit Weisman; Roy Beinart; Aharon Erez; Nira Koren-Morag; Ilan Goldenberg; Michael Eldar; Michael Glikson; David Luria
Journal:  J Interv Card Electrophysiol       Date:  2017-06-29       Impact factor: 1.900

Review 4.  Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia.

Authors:  E C Palma
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

5.  2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.

Authors:  Jonathan S Steinberg; Niraj Varma; Iwona Cygankiewicz; Peter Aziz; Paweł Balsam; Adrian Baranchuk; Daniel J Cantillon; Polychronis Dilaveris; Sergio J Dubner; Nabil El-Sherif; Jaroslaw Krol; Malgorzata Kurpesa; Maria Teresa La Rovere; Suave S Lobodzinski; Emanuela T Locati; Suneet Mittal; Brian Olshansky; Ewa Piotrowicz; Leslie Saxon; Peter H Stone; Larisa Tereshchenko; Mintu P Turakhia; Gioia Turitto; Neil J Wimmer; Richard L Verrier; Wojciech Zareba; Ryszard Piotrowicz
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05       Impact factor: 1.468

Review 6.  [Long term electrocardiography (Holter monitoring)].

Authors:  Axel Brandes; Klaus-Peter Bethge
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-10-25

7.  Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).

Authors:  Linda G Jones; Mo-Kyung Sin; Fadi G Hage; Raya E Kheirbek; Charity J Morgan; Michael R Zile; Wen-Chih Wu; Prakash Deedwania; Gregg C Fonarow; Wilbert S Aronow; Sumanth D Prabhu; Ross D Fletcher; Ali Ahmed; Richard M Allman
Journal:  Circ Heart Fail       Date:  2014-12-05       Impact factor: 8.790

Review 8.  Nonsustained ventricular tachycardia in dilated cardiomyopathy.

Authors:  Frank A Cuoco; Steven N Singh
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

9.  Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-09-01

10.  Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.

Authors:  Rudolph F Evonich; Alok Maheshwari; Joseph C Gardiner; Atul Khasnis; Sricharan Kantipudi; John H Ip; Denise Grimes; Gregory Hayter; Ranjan K Thakur
Journal:  J Interv Card Electrophysiol       Date:  2004-08       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.